Peptide receptor radionuclide therapy

Annals of the New York Academy of Sciences

Volumn 1014, Issue , 2004, Pages 234-245

  Krenning, Eric P ^a   Kwekkeboom, Dik J ^a   Valkema, Roelf ^a   Pauwels, Stanislas ^b   Kvols, Larry K ^c   De Jong, Marion ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^c H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

Bombesin; npy; Peptides; Radionuclide therapy; Somatostatin

Indexed keywords

BOMBESIN DERIVATIVE; FLUOROURACIL; LANTREOTIDE[1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID Y 90]; NEUROPEPTIDE Y DERIVATIVE; OCTREOTATE[3 TYROSINE 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID LU 177]; OCTREOTIDE[3 TYROSINE 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID Y 90]; PENTETREOTIDE; PENTETREOTIDE IN 111; RADIOPHARMACEUTICAL AGENT; SOMATOSTATIN DERIVATIVE; STREPTOZOCIN; UNCLASSIFIED DRUG;

BONE MARROW; BONE MARROW TOXICITY; BREAST CARCINOMA; CANCER CHEMOTHERAPY; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; GENE OVEREXPRESSION; HUMAN; ISOTOPE LABELING; KIDNEY TUBULE ABSORPTION; LIVER TOXICITY; LYMPH NODE METASTASIS; MAXIMUM TOLERATED DOSE; MYELODYSPLASTIC SYNDROME; NEPHROTOXICITY; NEUTROPENIA; PROGNOSIS; PROSTATE CANCER; RECEPTOR DENSITY; REVIEW; SIDE EFFECT; THROMBOCYTOPENIA; THYROID MEDULLARY CARCINOMA;

EID: 2342665696     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1196/annals.1294.026     Document Type: Review

References (68)

1. REUBI, J.C. et al. 1990. Somatostatin receptors in malignant tissues. J. Steroid. Biochem. Mol. Biol. 37: 1073-1077.
2. REUBI, J.C. et al. 1991. In vitro and in vivo detection of somatostatin receptors in human malignant tissues. Acta Oncol. 30: 463-468.
3. REUBI, J.C. et al. 1992. Somatostatin receptors in human cancer: incidence, characteristics, functional correlates and clinical implications. J. Steroid. Biochem. Mol. Biol. 43: 27-35.
4. 3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur. J. Nucl. Med. 20: 716-731.
5. KRENNING, E.P., W.H. BAKKER, W.A. BREEMAN, et al. 1989. Localisation of endocrine-related tumours with radioiodinated analogue of somatostatin. Lancet 1: 242-244.
6. KRENNING, E.P. et al. 1992. Somatostatin receptor scintigraphy with indium-111-DTPA-D-Phe-1-octreotide in man: metabolism, dosimetry and comparison with iodine-123-Tyr-3-octreotide. J. Nucl. Med. 33: 652-658.
7. GOLDSMITH, S.J. et al. 2000. Role of nuclear medicine in the evaluation of the solitary pulmonary nodule. Semin. Ultrasound CT MR 21: 129-138.
8. BLUM, J. et al. 2000. A multicenter trial with a somatostatin analog (99m)Tc depreotide in the evaluation of solitary pulmonary nodules. Chest 117: 1232-1238.
9. BEHR, T.M. et al. 2002. Cholecystokinin-B/gastrin receptor-targeting peptides for staging and therapy of medullary thyroid cancer and other cholecystokinin-B receptor-expressing malignancies. Semin. Nucl. Med. 32: 97-109.
10. KWEKKEBOOM, D.J. et al. 2000. Cholecystokinin receptor imaging using an octapeptide DTPA-CCK analogue in patients with medullary thyroid carcinoma. Eur. J. Nucl. Med. 27: 1312-1317.
11. VAN HAGEN, P.M. et al. 1996. Visualization of the thymus by substance P receptor scintigraphy in man. Eur. J. Nucl. Med. 23: 1508-1513.
12. BEHR, T.M. et al. 1998. Targeting of cholecystokinin-B/gastrin receptors in vivo: preclinical and initial clinical evaluation of the diagnostic and therapeutic potential of radiolabelled gastrin. Eur. J. Nucl. Med. 25: 424-430.
13. BEHR, T.M. et al. 2001. Imaging tumors with peptide-based radioligands. Q. J. Nucl. Med. 45: 189-200.
14. BEHR, T.M. et al. 1999. Cholecystokinin-B/gastrin receptor binding peptides: preclinical development and evaluation of their diagnostic and therapeutic potential. Clin. Cancer. Res. 5 (10 Suppl): 3124s-3138s.
15. REUBI, C. et al. 2002. Co-expressed peptide receptors in breast cancer as a molecular basis for in vivo multireceptor tumour targeting. Eur. J. Nucl. Med. Mol. Imaging 29: 855-862.
16. REUBI, J.C. et al 2001. Y(1)-mediated effect of neuropeptide Y in cancer: breast carcinomas as targets. Cancer Res. 61: 4636-4641.
17. REUBI, J.C. et al. 1997. Cholecystokinin(CCK)-A and CCK-B/gastrin receptors in human tumors. Cancer Res. 57: 1377-1386.
18. REUBI, J.C. et al. 2000. Vasoactive intestinal peptide/pituitary adenylate cyclase-activating peptide receptor subtypes in human tumors and their tissues of origin. Cancer Res. 60: 3105-3112.
19. VIRGOLINI, I. et al. 1995. Vasoactive intestinal peptide receptor scintigraphy. J. Nucl. Med. 36: 1732-1739.
20. 123I-vasoactive intestinal peptide (VIP) receptor scanning: update of imaging results in patients with adenocarcinomas and endocrine tumors of the gastrointestinal tract. Nucl. Med. Biol. 23: 685-692.
21. VIRGOLINI, I. et al. 1998. Indium-111-DOTA-lanreotide: biodistribution, safety and radiation absorbed dose in tumor patients. J. Nucl. Med. 39: 1928-1936.
22. WEINER, R.E. et al. 2002. Radiolabeled peptides in the diagnosis and therapy of oncological diseases. Appl. Radiat. Isot. 57: 749-763.
23. KRENNING, E.P. et al. 1994. Somatostatin-receptor scintigraphy in gastroenteropancreatic tumors. An overview of European results. Ann. N. Y. Acad. Sci. 733: 416-424.
24. KWEKKEBOOM, D.J. et al. 2000. Peptide receptor imaging and therapy. J. Nucl. Med. 41: 1704-1713.
25. REUBI, J.C. et al. 2000. Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur. J. Nucl. Med. 27: 273-282.
26. VALKEMA, R. et al. 2002. Phase I study of peptide receptor radionuclide therapy with [In-DTPA]octreotide: the Rotterdam experience. Semin. Nucl. Med. 32: 110-122.
27. 111In- pentetreotide. State of the art and perspectives. Q. J. Nucl. Med. 44: 88-95.
28. ANTHONY, L.B. et al. 2002. Indium-111-pentetreotide prolongs survival in gastroenteropancreatic malignancies. Semin. Nucl. Med. 32: 123-132.
29. DE JONG, M. et al. 1998. Comparison of (111)In-labeled somatostatin analogues for tumor scintigraphy and radionuclide therapy. Cancer Res. 58: 437-441.
30. 3] octreotide as carriers for somatostatin receptor-targeted scintigraphy and radionuclide therapy. Int J. Cancer 75: 406-411.
31. DE JONG, M. et al. 2001. Receptor-targeted radionuclide therapy using radiolabelled somatostatin analogues: tumour size versus curability. Eur. J. Nucl. Med. 28: 1026P.
32. DE JONG, M. et al. 2001.Tumor response after [(90)Y-DOTA(0),Tyr(3)] octreotide radionuclide therapy in a transplantable rat tumor model is dependent on tumor size. J. Nucl. Med. 42: 1841-1846.
33. 3-octreotide versus F-18-FDG-PET for evaluation of somatostatin receptor-mediated radionuclide therapy. Ann. Oncol. 12 (Suppl 2): S41-S45.
34. HEPPELER, A. et al. 1999. Radiometal-labelled macrocyclic chelator-derivatised somatostatin analogue with superb tumour-targeting properties and potential for receptor-mediated internal radiotherapy. Chem. Eur. J. 5: 1974-1981.
35. 111In-DTPA-octreotide in the same patients: biodistribution, kinetics, organ and tumor uptake. J. Nucl. Med. 40: 762-767.
36. CHINOL, M. et al. 2002. Receptor-mediated radiotherapy with Y-DOTA-D-Phe-Tyr-octreotide: the experience of the European Institute of Oncology Group. Semin. Nucl. Med. 32: 141-147.
37. 3-octreotide. Eur. J. Nucl. Med. 28: 426-434.
38. 90Y-DOTATOC: results of a phase I study. J. Nucl. Med. 42: 36P.
39. 90Y-DOTATOC) in the treatment of neuroendocrine tumours: a clinical phase II study. Ann. Oncol. 12: 941-945.
40. 90Y-DOTATOC. J. Nucl. Med. 43: 610-616.
41. WALDHERR, C. et al. 2002. Does tumor response depend on the number of treatment sessions at constant injected dose using 90yttrium-DOTATOC in neuroendocrine tumors? Eur. J. Nucl. Med. 29: S100.
42. DE JONG, M. et al. 2002. Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings. Semin. Nucl. Med. 32: 133-140.
43. SMITH, M.C. et al. 2000. OctreoTher: ongoing early clinical development of a somatostatin-receptor-targeted radionuclide antineoplastic therapy. Digestion 62 (Suppl 1): 69-72.
44. 90Y-SMT487 (OctreoTher) in patients with somatostatin receptor-positive tumors. J. Nucl. Med. 43: 33P.
45. 90Y-SMT487 (OctreoTher). J. Nucl. Med. 41: 111P.
46. 90Y- labelled peptidic vector DOTA-TOC to control gliomas of WHO grades II and III: an extended pilot study. Eur. J. Nucl. Med. Mol. Imaging 29: 486-493.
47. VIRGOLINI, I. et al. 2002. In- and Y-DOTA-lanreotide: results and implications of the MAURITIUS trial. Semin. Nucl. Med. 32: 48-155.
48. VIRGOLINI, I. et al. 1999. "MAURITIUS": tumour dose in patients with advanced carcinoma. Ital. J. Gastroenterol. Hepatol. 31 (Suppl 2): S227-S230.
49. VIRGOLINI, I. et al. Experience with indium-111 and yttrium-90-labeled somatostatin analogs. Curr. Pharm. Des. 8: 1781-1807.
50. 0]octreotide in patients. Eur. J. Nucl. Med. 28: 1319-1325.
51. 177Lu-DOTA(0),Tyr3] octreotate for somatostatin receptor-targeted radionuclide therapy. Int. J. Cancer 92: 628-633.
52. 3]octreotate in patients with neuroendocrine tumors: interim results. Eur. J. Nucl. Med. 30 (Suppl 2): S231.
53. 90Y-DOTATOC. Eur. J. Nucl. Med. 28: 1552-1554.
54. BEHR, T.M. et al. 2002. Nephrotoxicity versus anti-tumour efficacy in radiopeptide therapy: facts and myths about the Scylla and Charybdis. Eur. J. Nucl. Med. Mol. Imaging 29: 277-279.
55. BOERMAN, O.C. et al. 2001. Between the Scylla and Charybdis of peptide radionuclide therapy: hitting the tumor and saving the kidney. Eur. J. Nucl. Med. 28: 1447-1449.
56. VALKEMA, R. et al. 2001. Effective and safe inhibition of renal uptake of radiolabeled peptides by combined lysine and arginine infusion. J. Nucl. Med. 42: 37P.
57. ROLLEMAN, E.J. et al. 2003. Safe and effective inhibition of renal uptake of radiolabelled octreotide by a combination of lysine and arginine. Eur. J. Nucl. Med. Mol. Imaging 30: 9-15.
58. REUBI, J.C. et al. 1997. Localization of cholecystokinin A and cholecystokinin B-gastrin receptors in the human stomach. Gastroenterology 112: 1197-1205.
59. 111In-labeled nonsulfated CCK8 analog: a peptide for CCK-B receptor-targeted scintigraphy and radionuclide therapy. J. Nucl. Med. 40: 2081-2087.
60. REUBI, J.C. et al. 2002. Bombesin receptor subtypes in human cancers: detection with the universal radioligand (125)I-[D-Tyr(6), beta-Ala(11), Phe(13), NLE(14)] bombesin(6-14). Clin. Cancer Res. 8: 1139-1146.
61. MARKWALDER, R. et al. 1999. Gastrin-releasing peptide receptors in the human prostate: relation to neoplastic transformation. Cancer Res. 59: 1152-1159.
62. SCHMITT, J.S. et al. 2001. DOTA-NOC, a high affinity ligand of the somatostatin receptor subtypes 2,3 and 5 for radiotherapy. J. Labelled Cpd. Radiopharm. 44: s697-s699.
63. O'DONOGHUE, J.A. et al. 1995. Relationships between tumor size and curability for uniformly targeted therapy with beta-emitting radionuclides. J. Nucl. Med. 36: 1902-1909.
64. 177Lu-labeled analogs only. J. Nucl. Med. 43: 123P-124P.
65. GUGGER, M. et al. 1999. Gastrin-releasing peptide receptors in non-neoplastic and neoplastic human breast. Am. J. Pathol. 155: 2067-2076.
66. DE VINCENTIS, G. et al. 2002. Phase I trial of technetium [Leu13] bombesin as cancer seeking agent: possible scintigrapbic guide for surgery? Tumori 88: S28-S30.
67. 99mTc bombesin. A preliminary report. Tumori 88: S25-S28.
68. DE JONG, M. et al. 2003. Radiolabelled peptides for tumour therapy: current status and future directions. Eur. J. Nucl. Med. 30: 463-469.